Comments on: Why Novartis Eyed The Eye Business http://www.pharmalot.com/2008/04/why-novartis-eyed-the-eye-business/ News, Comment and Conversation Fri, 10 Feb 2012 17:01:14 +0000 http://wordpress.org/?v=2.6.2 By: Cancer Patient http://www.pharmalot.com/2008/04/why-novartis-eyed-the-eye-business/#comment-264136 Cancer Patient Tue, 08 Apr 2008 14:32:11 +0000 http://www.pharmalot.com/2008/04/why-novartis-eyed-the-eye-business/#comment-264136 Novartis is essentially a management company. Dan has no right to speak about innovation - Novartis hasn't innovated anything. They "buy" their way into markets, dominate them with pricing management schemes, over market the potential of their drugs and enslave patients by buying KOL's opinions and affections. In short they are the spoilers for any company that would/could be the true innovators. Personally, they would do all cancer patients a favor if they would just leave this market. Hope eye care grows nicely for them and I wish them well. Leukemia patients and GIST patients have been left hanging - they can't find a follow up to Gleevec and now I hear the molecule they thought they had for T315I mutations is tanking big time. The problem is that they continue to try to block entry to other drugs that are far superior. All the while sucking money out of the sytem that can be better used elsewhere. Well, at least we can see, it never was about the patients - it never is... Novartis is essentially a management company. Dan has no right to speak about innovation - Novartis hasn’t innovated anything. They “buy” their way into markets, dominate them with pricing management schemes, over market the potential of their drugs and enslave patients by buying KOL’s opinions and affections.

In short they are the spoilers for any company that would/could be the true innovators.

Personally, they would do all cancer patients a favor if they would just leave this market.

Hope eye care grows nicely for them and I wish them well.

Leukemia patients and GIST patients have been left hanging - they can’t find a follow up to Gleevec and now I hear the molecule they thought they had for T315I mutations is tanking big time.

The problem is that they continue to try to block entry to other drugs that are far superior. All the while sucking money out of the sytem that can be better used elsewhere.

Well, at least we can see, it never was about the patients - it never is…

]]>